{"id":529669,"date":"2021-08-19T08:03:40","date_gmt":"2021-08-19T12:03:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/"},"modified":"2021-08-19T08:03:40","modified_gmt":"2021-08-19T12:03:40","slug":"briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/","title":{"rendered":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer"},"content":{"rendered":"<h2>\nBriaCell to utilize ImaginAb\u2019s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug.  19, 2021  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201c<strong>BriaCell<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc (\u201c<strong>ImaginAb<\/strong>\u201d), a market leading global biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies.<\/p>\n<p align=\"justify\">Under the terms of the agreement, ImaginAb will supply clinical doses of its market leading CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in a study implemented as part of BriaCell\u2019s ongoing Phase I\/IIa study with Incyte in metastatic or locally recurrent breast cancer patients. Specifically, ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology. No other terms are disclosed.<\/p>\n<p align=\"justify\">The CD8 ImmunoPET technology allows whole body visualization of increased CD8 T cells, especially those infiltrating and attacking tumors. BriaCell will use the technology to provide a readout of both safety and efficacy of its novel cancer immunotherapy.<\/p>\n<p align=\"justify\">Dr. Bill Williams, President and CEO of BriaCell, commented, \u201cImaginAb\u2019s cutting edge CD8 ImmunoPET technology has been used by leading cancer drug developers to more accurately analyze tumors and immune responses to cancer treatments. We look forward to working with the team of experts at ImaginAb to evaluate the safety and efficacy of BriaCell\u2019s immunotherapy treatments in patients with advanced breast cancer.\u201d<\/p>\n<p align=\"justify\">Ian Wilson, CEO of ImaginAb, stated, \u201cWe are delighted to welcome BriaCell as a new clinical partner, especially as it is the first time 89Zr-Df-Crefmirlimab will be used to image the response of breast cancer to their novel targeted immunotherapy treatment. We are excited about the benefits 89Zr-Df-Crefmirlimab can potentially bring to patients and how it could help BriaCell accelerate the development of its novel immunotherapy treatments.<\/p>\n<p align=\"justify\">\u201cImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reducing the length of trials and allowing new therapies to advance to market quicker, and may remove the need for repeat, painful biopsies, all of which could ultimately transform patient care.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8CUNoBHHIBn2m9T9zDAHoN2NlwTsyePwkUs2pu2SSKYEU6915eQxTynVcCI8EZRc3bFtTRtYvnFsZjaS0Tv8Eg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About ImaginAb<\/strong>\n      <\/p>\n<p align=\"justify\">ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity.<\/p>\n<p align=\"justify\">ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets, including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb\u2019s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb\u2019s pipeline and technology, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Okr6aHNoUZn9v6CvyxzuNNQYmDOJJnQrnWmwxIg7K6gZQyNCrFLamh1tMIZsGBJly8PEBDNZdM3Z5A60cMNDexguz_dEwtajR5H-dXyENa0=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.imaginab.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading &#8220;Risks and Uncertainties&#8221; in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1ZXAOFU9uQn5zaWrl3bbVRVFihnbH2rLEsYyNMUAcwg2xaOyWA1G3S6lDUQJ7rMtV3_7L3oARuovEGaWiAOU1A==\" rel=\"nofollow noopener\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p>\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sKgd7XTKqTolRKDWI5GOAsuQARynAzNAyHdhsg33r_EgAAD8KHI2iQyovi9bhFafZep6r2HENwhKTdaNUEmejg==\" rel=\"nofollow noopener\" target=\"_blank\">info@briacell.com<\/a><\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Director of Public Relations<br \/>CORE IR<br \/>917-885-7378<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rM9TPwtm3rsLAPjprPjeIW6IRLAMPeQg9pFTB_dXVe5l2v3KRaBI_k5-58OHHxY2oocwg2ZuNZX2hCLcopNoxg==\" rel=\"nofollow noopener\" target=\"_blank\">julesa@coreir.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_hTjLSvij80cXgbKcxILZme8-vtS5Ud3F_JmwUrbtLbIehNQXUUx2cxo3Mbv93P7lBEkpQzJ569y9cUl_v3Nf_FLg9TtHCyR_Ev1E_55yMk=\" rel=\"nofollow noopener\" target=\"_blank\">investors@briacell.com<\/a><\/p>\n<p>\n        <strong>ImaginAb<\/strong><br \/>\n        <br \/>Ian Wilson<br \/>CEO<br \/>310-645-1211<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X-jIUtgvQlAv99d5EAvouk11srY6T6zsGEE6wBbSKWS6OLMdg5gkY1ZBcUy2-mJNHmV93Fkz_GfmJ33K1VhDog==\" rel=\"nofollow noopener\" target=\"_blank\">info@imaginab.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTcxYzY2ZGItYmMyMi00YzYwLTg3NGMtYzZlOGIwZWY5ODNmLTExMDIyMjk=\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BriaCell to utilize ImaginAb\u2019s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc (\u201cImaginAb\u201d), a market leading global biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies. Under the terms of the agreement, ImaginAb will supply clinical doses of its market leading CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in a study implemented as part of BriaCell\u2019s ongoing Phase I\/IIa study with Incyte &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-529669","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BriaCell to utilize ImaginAb\u2019s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc (\u201cImaginAb\u201d), a market leading global biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies. Under the terms of the agreement, ImaginAb will supply clinical doses of its market leading CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in a study implemented as part of BriaCell\u2019s ongoing Phase I\/IIa study with Incyte &hellip; Continue reading &quot;BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-19T12:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer\",\"datePublished\":\"2021-08-19T12:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/\"},\"wordCount\":892,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/\",\"name\":\"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\",\"datePublished\":\"2021-08-19T12:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk","og_description":"BriaCell to utilize ImaginAb\u2019s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc (\u201cImaginAb\u201d), a market leading global biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies. Under the terms of the agreement, ImaginAb will supply clinical doses of its market leading CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in a study implemented as part of BriaCell\u2019s ongoing Phase I\/IIa study with Incyte &hellip; Continue reading \"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-19T12:03:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer","datePublished":"2021-08-19T12:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/"},"wordCount":892,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/","name":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=","datePublished":"2021-08-19T12:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTg1OSM0MzY1NzUwIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=529669"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=529669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=529669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=529669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}